Posted Jul 07, 2026
Fast, Flexible Follow-Up with Telehealth
Improving behavioral health outcomes doesn’t have to be complex. Telehealth and Medication-Assisted Treatment (MAT) help to expand access, support recovery, and can improve your overall quality performance.
Review these resources for Initiation and Engagement of Substance Use Disorder Treatment (IET) and Follow-Up After Emergency Department Visit for Substance Use (FUA).
Telehealth makes it easier to deliver timely care and stay connected to your patients.
Key benefits
Medication-Assisted Treatment (MAT) is a proven, evidence-based approach for treating substance use disorders—supporting both recovery and quality measure compliance.
Start the conversation—encourage patients to consider MAT as part of their recovery plan.
Use these steps to improve outcomes and meet quality measures:
The providers listed can help ensure patients are seen within the required seven-day quality measure, especially while awaiting follow-up within your network.
Note: Ophelia offers virtual care for opioid use disorders, including medication management and ongoing support.
| Provider Name | Referral Phone | Services | Languages | Website Link (schedule or submit a referral) |
|---|---|---|---|---|
| Valera Health | 1-646-450-7748 | Mental Health | Mandarin, Cantonese, Spanish | valerahealth.com |
| PM Pediatrics (MH) Pediatric Urgent Care | 1-888-764-4161 | Mental Health | Spanish | pmpediatriccare.com |
| Brave Health | 1-305-902-6347 | Mental Health | Mandarin, Cantonese, Spanish | bebravehealth.com |
| Wholeview Wellness | 1-212-204-8430 | Outpatient Treatment Rehab for Substance Abuse | English, Spanish | wholeview.co |
| Ophelia Health | 1-212-585-2144 | Online Treatment for Opioid Addiction and Dependence | English | ophelia.com |
| Empire State Psychiatry | 1-646-553-6378 | Mental Health, Medication Management, Spravato | English | empirestatepsychiatry.com |
| Description | Prescription |
|---|---|
| Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
| Antagonist | Naltrexone (oral and injectable) |
| Other | Acamprosate (oral; delayed-release tablet) |
| Description | Prescription |
|---|---|
| Antagonist | Naltrexone (oral & injectable) |
| Partial agonist | Buprenorphine (sublingual tablet) |
| Partial agonist | Buprenorphine (injection & implant) |
| Partial agonist | Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) |
Coverage is provided by Healthfirst Health Plan, Inc., Healthfirst PHSP, Inc., and/or Healthfirst Insurance Company, Inc. (together, “Healthfirst”).